KDR and neoplasm: Indeed, the combination of a FOXM1 inhibitor with an anti-VEGFR2 monoclonal antibody improved tumor control compared to a single agent in hepatocellular carcinoma (HCC) tumor xenografts and provided a novel approach for the treatment of advanced HCC [70].